drugset / Trial / NCT01133873

Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects

NCT01133873 ↗

Phase 4 Terminated 48 enrolled Xanodyne Pharmaceuticals
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the daily maximum tolerated dose of propoxyphene napsylate in healthy subjects.

Timeline

Start
2010-06
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Propoxyphene napsylate Unknown 100 mg Oral

Indications

No indication recorded.